Preclinical News and Research

RSS

Gene signature explains why 18F-FDG imaging performs better for PSMA-suppressed prostate cancer patients

Scientists have uncovered the genomic signature to explain why 18F-FDG imaging performs better than PSMA-targeted imaging for prostate cancer patients with low or no expression of the prostate-specific membrane antigen (PSMA).

23 Jul 2020

New strategy allows long-term, non-invasive tracking of cardiomyocytes

A new platform reported on today in STEM CELLS Translational Medicine (SCTM) will enable long-term tracking of cardiomyocytes produced from induced pluripotent stem cells (iPSCs) after implantation into the heart.

23 Jul 2020

Eikonoklastes Therapeutics announces closing of oversubscribed seed financing

Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases with unmet clinical need, today announced closing of an oversubscribed seed financing.

23 Jul 2020

Study: L-Grb2 has therapeutic efficacy in preclinical models of ovarian and uterine cancer

The cover for issue 29 of Oncotarget features, "In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model," by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling.

23 Jul 2020

Vesigen Therapeutics to develop and commercialize novel drug-delivery technologies

Harvard University's Office of Technology Development (OTD) and the Harvard T.H. Chan School of Public Health today announced the launch of Vesigen Therapeutics, a startup company that aims to overcome the challenge of delivering next-generation therapeutics, such as gene-editing complexes, RNA molecules, and other large proteins, to intracellular targets in specific tissues of interest.

23 Jul 2020

Arcturus and Duke-NUS announce approval of clinical trials for COVID-19 vaccine candidate

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, and Duke-NUS Medical School, Singapore's flagship research-intensive graduate entry medical school, today announced that the Clinical Trial Application for COVID-19 vaccine candidate LUNAR-COV19 has been approved to proceed by the Singapore Health Sciences Authority.

22 Jul 2020

Scientists isolate potent SARS-CoV-2 neutralizing antibodies from COVID-19 patients

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing the SARS-CoV-2 virus.

22 Jul 2020

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) issued a positive response to the Qualification Plan (QP) for glutamate dehydrogenase (GLDH) as a safety biomarker for drug-induced liver injury (DILI), developed by C-Path's Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC).

22 Jul 2020

Researchers identify potential new combination therapy to treat head and neck cancer

Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.

21 Jul 2020

Researchers develop world’s smallest, flexible scope for imaging blood vessels

A team of researchers led by the University of Adelaide and University of Stuttgart has used 3D micro-printing to develop the world's smallest, flexible scope for looking inside blood vessels.

21 Jul 2020

Mouse model of fatal COVID-19 developed for vaccine and drug testing

Now, a new study published on the preprint server bioRxiv in July 2020 presents an engineered transgenic mouse that reproduces the functional and clinical characteristics of severe human SARS-CoV-2 infection.

21 Jul 2020

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

A new study published on the preprint server medRxiv by a research group from the U.S. and Germany indicates that a novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) induces functional and proinflammatory T cell responses in almost all participants – marking another landmark achievement for this promising vaccine candidate.

21 Jul 2020

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

British Patient Capital announces a cornerstone commitment of $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund, to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases.

21 Jul 2020

3D imaging device provides a better understanding on the causes of heart attack

A team of researchers led by the University of Adelaide and University of Stuttgart has used 3D micro-printing to develop the world's smallest, flexible scope for looking inside blood vessels.

21 Jul 2020

Researchers receive $1.3 million grant to develop better treatments for Alzheimer's disease

Innovators at Purdue University have received new support as they work to develop solutions to what U.S. military officials call an alarming trend in dementia among wounded soldiers. The same researchers also seek solutions to better treat Alzheimer's disease.

21 Jul 2020

New nanoparticle vaccine for SARS-CoV-2 shows protective traits in preclinical study

A new nanoparticle vaccine for SARS-CoV-2, the virus that causes COVID-19, has shown hints of protection and immunity in a preclinical study, safely eliciting the production of antibodies and antiviral T cell responses in mice and pigtail macaques.

20 Jul 2020

COVID-19 vaccine displays protective traits in nonhuman primates

A replicating RNA vaccine, formulated with a lipid-based nanoparticle emulsion that goes by the acronym LION, produces antibodies against the COVID-19 coronavirus in mice and primates with a single immunization. These antibodies potently neutralize the virus.

20 Jul 2020

Josep Carreras Institute's spin-off aims to develop new immuno-oncological therapeutic tools

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's (Government of Catalonia) CERCA network, has created the OneChain Immunotherapeutics spin-off, the aim of which is to develop new immuno-oncological therapeutic tools with various preclinical candidates, based on CAR-T technology for different tumors, such as cortical T-cell acute lymphoblastic leukemia (coT-ALL), a rare subtype of leukemia that mainly affects children, and which has a poor prognosis.

20 Jul 2020

How immune cells switch to attack mode

Unraveling a key motif: The T lymphocytes of the immune system work to destroy infected cells or cancer cells. To do so, they have to identify the threat: Molecules perceived as foreign - so-called antigens - bind to the T-cell receptor on the T cell surface.

20 Jul 2020

Study shows how radiotherapy alters the behavior of immune cells in glioblastoma tumors

A Ludwig Cancer Research study has dissected how radiotherapy alters the behavior of immune cells known as macrophages found in glioblastoma (GBM) tumors and shown how these cells might be reprogrammed with an existing drug to suppress the invariable recurrence of the aggressive brain cancer.

16 Jul 2020

Preclinical News and Research

Gene signature explains why 18F-FDG imaging performs better for PSMA-suppressed prostate cancer patients

New strategy allows long-term, non-invasive tracking of cardiomyocytes

Eikonoklastes Therapeutics announces closing of oversubscribed seed financing

Study: L-Grb2 has therapeutic efficacy in preclinical models of ovarian and uterine cancer

Vesigen Therapeutics to develop and commercialize novel drug-delivery technologies

Arcturus and Duke-NUS announce approval of clinical trials for COVID-19 vaccine candidate

Scientists isolate potent SARS-CoV-2 neutralizing antibodies from COVID-19 patients

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

Researchers identify potential new combination therapy to treat head and neck cancer

Researchers develop world’s smallest, flexible scope for imaging blood vessels

Mouse model of fatal COVID-19 developed for vaccine and drug testing

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

3D imaging device provides a better understanding on the causes of heart attack

Researchers receive $1.3 million grant to develop better treatments for Alzheimer's disease

New nanoparticle vaccine for SARS-CoV-2 shows protective traits in preclinical study

COVID-19 vaccine displays protective traits in nonhuman primates

Josep Carreras Institute's spin-off aims to develop new immuno-oncological therapeutic tools

How immune cells switch to attack mode

Study shows how radiotherapy alters the behavior of immune cells in glioblastoma tumors

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics